205 related articles for article (PubMed ID: 36170295)
1. Mutations of tyrosine 467 in the human norepinephrine transporter attenuate HIV-1 Tat-induced inhibition of dopamine transport while retaining physiological function.
Strauss MJ; Porter KD; Quizon PM; Davis SE; Lin S; Yuan Y; Martinez-Muniz GA; Sun WL; Zhan CG; Zhu J
PLoS One; 2022; 17(9):e0275182. PubMed ID: 36170295
[TBL] [Abstract][Full Text] [Related]
2. Mutations at tyrosine 88, lysine 92 and tyrosine 470 of human dopamine transporter result in an attenuation of HIV-1 Tat-induced inhibition of dopamine transport.
Midde NM; Yuan Y; Quizon PM; Sun WL; Huang X; Zhan CG; Zhu J
J Neuroimmune Pharmacol; 2015 Mar; 10(1):122-35. PubMed ID: 25604666
[TBL] [Abstract][Full Text] [Related]
3. Mutations of Human DopamineTransporter at Tyrosine88, Aspartic Acid206, and Histidine547 Influence Basal and HIV-1 Tat-inhibited Dopamine Transport.
Quizon PM; Yuan Y; Zhu Y; Zhou Y; Strauss MJ; Sun WL; Zhan CG; Zhu J
J Neuroimmune Pharmacol; 2021 Dec; 16(4):854-869. PubMed ID: 33537927
[TBL] [Abstract][Full Text] [Related]
4. Mutation of tyrosine 470 of human dopamine transporter is critical for HIV-1 Tat-induced inhibition of dopamine transport and transporter conformational transitions.
Midde NM; Huang X; Gomez AM; Booze RM; Zhan CG; Zhu J
J Neuroimmune Pharmacol; 2013 Sep; 8(4):975-87. PubMed ID: 23645138
[TBL] [Abstract][Full Text] [Related]
5. Site-directed mutations near transmembrane domain 1 alter conformation and function of norepinephrine and dopamine transporters.
Guptaroy B; Fraser R; Desai A; Zhang M; Gnegy ME
Mol Pharmacol; 2011 Mar; 79(3):520-32. PubMed ID: 21149640
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type.
Eshleman AJ; Carmolli M; Cumbay M; Martens CR; Neve KA; Janowsky A
J Pharmacol Exp Ther; 1999 May; 289(2):877-85. PubMed ID: 10215666
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine residue 271 of the norepinephrine transporter is an important determinant of its pharmacology.
Paczkowski FA; Bryan-Lluka LJ
Brain Res Mol Brain Res; 2001 Dec; 97(1):32-42. PubMed ID: 11744160
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanism: the human dopamine transporter histidine 547 regulates basal and HIV-1 Tat protein-inhibited dopamine transport.
Quizon PM; Sun WL; Yuan Y; Midde NM; Zhan CG; Zhu J
Sci Rep; 2016 Dec; 6():39048. PubMed ID: 27966610
[TBL] [Abstract][Full Text] [Related]
9. Binding Mode of Human Norepinephrine Transporter Interacting with HIV-1 Tat.
Adeniran C; Yuan Y; Davis SE; Lin C; Xu J; Zhu J; Zhan CG
ACS Chem Neurosci; 2021 May; 12(9):1519-1527. PubMed ID: 33886267
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological properties of the naturally occurring Ala(457)Pro variant of the human norepinephrine transporter.
Paczkowski FA; Bönisch H; Bryan-Lluka LJ
Pharmacogenetics; 2002 Mar; 12(2):165-73. PubMed ID: 11875370
[TBL] [Abstract][Full Text] [Related]
11. Mutational effects of human dopamine transporter at tyrosine88, lysine92, and histidine547 on basal and HIV-1 Tat-inhibited dopamine transport.
Sun WL; Quizon PM; Yuan Y; Strauss MJ; McCain R; Zhan CG; Zhu J
Sci Rep; 2019 Mar; 9(1):3843. PubMed ID: 30846720
[TBL] [Abstract][Full Text] [Related]
12. SRI-32743, a novel allosteric modulator, attenuates HIV-1 Tat protein-induced inhibition of the dopamine transporter and alleviates the potentiation of cocaine reward in HIV-1 Tat transgenic mice.
Zhu J; Quizon PM; Wang Y; Adeniran CA; Strauss MJ; Jiménez-Torres AC; Patel P; Cirino TJ; Eans SO; Hammond HR; Deliscar LS; O'Hara P; Saini SK; Ofori E; Vekariya RH; Zhang S; Moukha-Chafiq O; Nguyen TH; Ananthan S; Augelli-Szafran CE; Zhan CG; McLaughlin JP
Neuropharmacology; 2022 Dec; 220():109239. PubMed ID: 36126727
[TBL] [Abstract][Full Text] [Related]
13. Dopamine and norepinephrine transporter-dependent c-Fos production in vitro: relevance to neuroadaptation.
Yatin SM; Miller GM; Madras BK
J Neurosci Methods; 2005 Apr; 143(1):69-78. PubMed ID: 15763138
[TBL] [Abstract][Full Text] [Related]
14. Role of Histidine 547 of Human Dopamine Transporter in Molecular Interaction with HIV-1 Tat and Dopamine Uptake.
Yuan Y; Quizon PM; Sun WL; Yao J; Zhu J; Zhan CG
Sci Rep; 2016 Jun; 6():27314. PubMed ID: 27250920
[TBL] [Abstract][Full Text] [Related]
15. Allosteric modulatory effects of SRI-20041 and SRI-30827 on cocaine and HIV-1 Tat protein binding to human dopamine transporter.
Sun WL; Quizon PM; Yuan Y; Zhang W; Ananthan S; Zhan CG; Zhu J
Sci Rep; 2017 Jun; 7(1):3694. PubMed ID: 28623359
[TBL] [Abstract][Full Text] [Related]
16. [
Strauss M; O'Donovan B; Ma Y; Xiao Z; Lin S; Bardo MT; Ortinski PI; McLaughlin JP; Zhu J
J Pharmacol Exp Ther; 2020 Aug; 374(2):241-251. PubMed ID: 32461322
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of the human norepinephrine transporter in intact 293-hNET cells exposed to desipramine.
Zhu MY; Blakely RD; Apparsundaram S; Ordway GA
J Neurochem; 1998 Apr; 70(4):1547-55. PubMed ID: 9523572
[TBL] [Abstract][Full Text] [Related]
18. Involvement of the NH2 terminal domain of catecholamine transporters in the Na(2+) and Cl(-)-dependence of a [3H]-dopamine uptake.
Syringas M; Janin F; Giros B; Costentin J; Bonnet JJ
Br J Pharmacol; 2001 Jun; 133(3):387-94. PubMed ID: 11375255
[TBL] [Abstract][Full Text] [Related]
19. The role of cysteines and histidins of the norepinephrine transporter.
Wenge B; Bönisch H
Neurochem Res; 2013 Jul; 38(7):1303-14. PubMed ID: 23525969
[TBL] [Abstract][Full Text] [Related]
20. The role of the conserved GXXXRXG motif in the expression and function of the human norepinephrine transporter.
Sucic S; Bryan-Lluka LJ
Brain Res Mol Brain Res; 2002 Dec; 108(1-2):40-50. PubMed ID: 12480177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
